Sequential treatment in advanced non–small cell lung cancer harboring EGFR mutations

BACKGROUND: Epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) are standard treatments for advanced EGFR-mutated non–small cell lung cancer (NSCLC) patients. Osimertinib is an effective therapy for NSCLC patients with acquired resistance due to T790M mutation after first- and...

Descripción completa

Detalles Bibliográficos
Autores principales: Hsu, Ping-Chih, Chang, John Wen-Cheng, Chang, Ching-Fu, Huang, Chen-Yang, Yang, Cheng-Ta, Kuo, Chih-Hsi Scott, Fang, Yueh-Fu, Wu, Chiao-En
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9619270/
https://www.ncbi.nlm.nih.gov/pubmed/36305280
http://dx.doi.org/10.1177/17534666221132731

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9619270/
https://www.ncbi.nlm.nih.gov/pubmed/36305280
http://dx.doi.org/10.1177/17534666221132731

Ejemplares similares